KR950007857A - 경구투여용 라파마이신 제제 - Google Patents

경구투여용 라파마이신 제제 Download PDF

Info

Publication number
KR950007857A
KR950007857A KR1019940024666A KR19940024666A KR950007857A KR 950007857 A KR950007857 A KR 950007857A KR 1019940024666 A KR1019940024666 A KR 1019940024666A KR 19940024666 A KR19940024666 A KR 19940024666A KR 950007857 A KR950007857 A KR 950007857A
Authority
KR
South Korea
Prior art keywords
rapamycin
composition
surfactant
polyethylene glycol
dimethylacetamide
Prior art date
Application number
KR1019940024666A
Other languages
English (en)
Inventor
폴 와라니스 로버트
웨이몬드 레오나드 토마스
Original Assignee
이곤 이. 버그
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이곤 이. 버그, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 이곤 이. 버그
Publication of KR950007857A publication Critical patent/KR950007857A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

본 발명은 제제 100㎎당 라파마이신 약 0.05 내지 약 10.0g, N, N-디메틸아세트아미드 약 0.1 내지 약 25㎖, 계면활성제 약 0.1 내지 약 10㎎, 약 10㎖ 및 PEG 400 약 65 내지 약 99.8㎖를 함유하는 경구용의 신규한 라파마이신 제제에 관한 것이다.

Description

경구투여용 라파마이신 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 조성물 100㎎당 라파마이신 약 0.05 내지 약 10.0g, N, N-디메틸아세트아미드 약 0.1 내지 약 25㎖, 계면활성제 약 0.1 내지 약 10㎖ 및 폴리에틸렌 글리콜 약 65 내지 약 99.8㎖를 포함하는 조성물.
  2. 제1항에 있어서, 조성물 100㎎당 라파마이신 약 0.10 내지 약 8.0g, N, N-디메틸아세트아미드 약 0.5 내지 약 20㎖, 계면활성제 약 0.5 내지 약 20㎖ 및 폴리에틸렌 글리콜 약 72 내지 약 99㎖를 포함하는 조성물.
  3. 제1항에 있어서, 조성물 100㎎당 라파마이신 약 0.5 내지 약 5.0g, N, N-디에틸아세트아미드 약 1.0 내지 약 20㎖, 계면활성제 약 1.0 내지 약 5.0㎖ 및 폴리에틸렌 글리콜 약 75내지 약 98㎖를 포함하는 조성물.
  4. 제1항에 있어서, 조성물 100㎎당 라파마이신 약 5.0g, N, N-디메틸아세트아미드 20㎖, 계면활성제 10㎖ 및 폴리에틸렌 글리콜 400을 100㎖가 되도록 충분량 함유하는 조성물.
  5. 적어도 제1성분으로서의 라파마이신 5.0g과 제2성분으로서의 N, N-디메틸아세트아미드 20㎖, 계면활성제 10㎖ 및 폴리에틸렌 글리콜 400을 100㎖가 되도록 충분량 포함하는 경구용 다성분 라파마이신 제제.
  6. 적어도 제1성분으로서의 라파마이신 2.5g과 10㎖가 되는 충분량의 N, N-디메틸아세트아미드와 제2성분으로서의 계면활성제 5㎖와 40㎖가 되는 충분량의 폴리에틸렌 글리콜 400을 포함하는 경구용 다성분 라파마이신제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940024666A 1993-09-30 1994-09-29 경구투여용 라파마이신 제제 KR950007857A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12952493A 1993-09-30 1993-09-30
US?08/129,524? 1993-09-30

Publications (1)

Publication Number Publication Date
KR950007857A true KR950007857A (ko) 1995-04-15

Family

ID=22440418

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940024666A KR950007857A (ko) 1993-09-30 1994-09-29 경구투여용 라파마이신 제제

Country Status (10)

Country Link
EP (1) EP0650730A1 (ko)
JP (1) JPH07149656A (ko)
KR (1) KR950007857A (ko)
CN (1) CN1109746A (ko)
AU (1) AU7420494A (ko)
BR (1) BR9403947A (ko)
CA (1) CA2133174A1 (ko)
FI (1) FI944534A (ko)
HU (1) HUT71131A (ko)
IL (1) IL111003A0 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
US5880101A (en) * 1994-06-28 1999-03-09 Dr. Zerle Gmbh Clinical uses of polyene macrolides
CA2231404C (en) 1994-11-03 2009-02-17 Arzneimittelwerk Dresden Gmbh Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
ATE385795T1 (de) 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
EP1539157B1 (en) * 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
US20050032674A1 (en) * 2003-07-03 2005-02-10 Kelly Ciaran P. SAIF, an anti-inflammatory factor, and methods of use thereof
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20080275076A1 (en) * 2005-03-08 2008-11-06 Per Holm Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof
DE102008059201A1 (de) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2012092421A2 (en) 2010-12-30 2012-07-05 Surmodics, Inc. Composition for intravascular delivery of therapeutic composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2148224T3 (es) * 1992-03-30 2000-10-16 American Home Prod Formulacion de rapamicina para inyecciones intravenosas.

Also Published As

Publication number Publication date
BR9403947A (pt) 1995-06-13
HUT71131A (en) 1995-11-28
EP0650730A1 (en) 1995-05-03
HU9402785D0 (en) 1994-12-28
FI944534A (fi) 1995-03-31
CN1109746A (zh) 1995-10-11
JPH07149656A (ja) 1995-06-13
IL111003A0 (en) 1994-11-28
CA2133174A1 (en) 1995-03-31
FI944534A0 (fi) 1994-09-29
AU7420494A (en) 1995-04-13

Similar Documents

Publication Publication Date Title
KR950007856A (ko) 경구 투여용 라파마이신 제형
KR950007857A (ko) 경구투여용 라파마이신 제제
ES2098672T3 (es) Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3.
ATE165971T1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
FR2708606B1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CA2166388A1 (en) Antifungal composition for external use retentive in stratum corneum
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
DE69521693T2 (de) Taxanderivate enthaltende arzneizubereitungen
PT637248E (pt) Composicao farmaceutica contendo um derivado de ciclosporina
FR2697841B1 (fr) Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
FR2697019B1 (fr) Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2703995B1 (fr) 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR2712288B1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712289B1 (fr) Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2705097B1 (fr) Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2705094B1 (fr) Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
HUP0004362A2 (hu) Karbamazepint vagy származékait tartalmazó parenterális készítmények
KR940006594A (ko) 후박 추출성분을 포함하는 치주질환 예방 치료제 조성물
KR910002792A (ko) 1-치환된-2-(3-아미노-1-프로피닐)피롤리딘 유도체, 그에 의한 중추 콜린성 기능 장해 치료 방법 및 그로구성되는 제약학적 조성물
ATE136783T1 (de) Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung
MX9304466A (es) Derivados de arginina.
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid